A Comparison of the Safety and Comfort of AC-170

NCT01495338 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Normal Ocular Health

Interventions

DRUG: AC-170 0.17%
DRUG: AC-170 0.24% (Formulation 1)
DRUG: AC-170 0.24% (Formulation 2)
DRUG: Olopatadine hydrochloride 0.2%/Tears Naturale II

Sponsor

Aciex Therapeutics, Inc.